GlobeNewswire·Jul 21, 2026, 4:01 PM ET

Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

NRIX

Nurix Therapeutics announced the closing of its global collaboration agreement with Roche to co-develop and co-commercialize bexobrutideg after the expiration of the Hart-Scott-Rodino Act waiting period.
The deal includes an upfront cash payment of $700 million to Nurix & eligibility for up to $2.3 billion in total development, regulatory, & sales milestones.
Development costs for bexobrutideg will be shared 40% by Nurix & 60% by Roche.
Profits & losses from U.S. commercialization will be split equally between the two parties, while Roche handles commercialization outside the U.S. with Nurix eligible for royalties in the low- to high-teens.
Both companies will jointly advance a clinical program for bexobrutideg targeting chronic lymphocytic leukemia (CLL), B-cell malignancies, multiple sclerosis (MS), & chronic spontaneous urticaria (CSU).
Bexobrutideg (NX-5948) is an investigational, orally bioavailable, brain-penetrant BTK degrader currently being evaluated in pivotal Phase 2 trials for relapsed/refractory CLL & Phase 1a/1b studies for B-cell malignancies.
Additional trials include a Phase 3 study comparing bexobrutideg to pirtobrutinib in CLL, a Phase 1/2 combination study with venetoclax, & a first-in-human safety study for a new tablet formulation to support immunology & neurology indications.
Nurix retains a pipeline of other targeted protein degradation medicines in collaboration with partners including Gilead, Sanofi, & Pfizer, while focusing on advancing bexobrutideg as a potential best-in-class therapy.